A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Enzalutamide (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary) ; Rilimogene galvacirepvec; Rilimogene glafolivec
- Indications Prostate cancer
- Focus Therapeutic Use
- 29 Sep 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 10 Jun 2017 Biomarkers information updated
- 28 Dec 2016 Status changed from recruiting to active, no longer recruiting.